Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of LY900014 vs Insulin Lispro in T2DM
NCT02703337Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours. Started Mar 2016; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02703337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703337.